Objective: To evaluate which factors influence maximum gain in best-corrected visual acuity after intravitreal injection of Bevacizumab as treatment for diffuse diabetic macular edema.
Methods: This was a prospective, interventional trial including 112 eyes of 100 participants. Visual outcomes measured by change in visual acuity (VA) score, proportion gaining ?15 letters, and change in central retinal thickness (CRT), presence of macular ischaemia, IS/OS integrity.
Results: Mean change in the VA score was 9.2 ± 2.3 SD letters with a total of 79 eyes gaining ?15 letters. Change in median CRT was 81.5 ????m. Younger age, higher baseline VA score, shorter duration of Diabetic Macular Edema (DME), absence of macular ischemia and an intact IS/OS junction were significantly associated with greater VA score improvement.
Conclusion: Pronounced macular edema and intact IS/OS junction may have a positive impact, and marked macular ischemia and a high preoperative best-corrected visual acuity may have a negative impact, on an increase in best-corrected visual acuity after intravitreal Bevacizumab injection in patients with diabetic macular edema.
Real Time Impact Factor:
Author Name: Sunny Kumar Gupta, Ishan Yadav, Sujit Deshmukh, Rajendra P Maurya, V P Singh.
URL: View PDF
Keywords: Bevacizumab, Diabetic macular edema, IS/OS junction, Macular ischaemia.